Cardinal Health (CAH)
NYSEHealth CareMedical DistributionSnapshot 2026-07-07
$239.69+0.91%
Close 2026-07-07 · 1-day change
Reading CAH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CAH free→NYSEHealth CareMedical DistributionSnapshot 2026-07-07
Reading CAH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CAH free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is a durable compounder with a focus on steady earnings growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to increasing earnings per share (EPS) guidance.
The market currently prices CAH at a premium compared to its peers, indicating that expectations for future performance are somewhat high. There is a low expectations gap, suggesting that the market has already factored in some level of growth.
Management is on track to improve EPS and free cash flow, with recent results showing positive trends. However, there is a moderate risk due to a recent earnings miss, which may affect investor sentiment.
The long-term thesis hinges on the performance of sector bellwethers like MCK, COR, and HSIC. If these companies continue to perform well, CAH could benefit from positive sector momentum, but any downturn in their performance could negatively impact CAH.
Overall, CAH is positioned well for the next few years, but it faces risks that could affect its credibility and growth. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that recent financial performance remains strong and is holding in the top half of its industry. There are no new threats identified that would weaken this outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Changes in EPS guidance signal the company's financial health and growth potential. A raise suggests strong performance.
Confirms:Fiscal year 2026 non-GAAP EPS guidance raised to $10.70 to $10.80.
Disproves:Guidance is now below $10.70. This suggests possible problems with performance.
Why it matters: Free cash flow guidance reflects the company's ability to generate cash. Higher cash flow supports growth and shareholder returns.
Confirms:Free cash flow guidance raised to $3.3 to $3.7 billion, indicating strong cash generation.
Disproves:Guidance is lower or stays the same. This shows possible cash generation problems.
Why it matters: An update on EPS guidance will show how well the company is managing growth. Investors look for strong guidance to support confidence in future earnings.
Confirms:Non-GAAP EPS guidance is now $10.70 to $10.80. This shows strong performance.
Disproves:Guidance is lower or stays the same. This suggests weaker performance expectations.
Why it matters: Earnings results will show how the company is doing. They can affect investor feelings. Strong results can help stock prices go up.
Confirms one read:Earnings results show non-GAAP EPS above $3.17, indicating strong growth.
Confirms the other:Earnings results show non-GAAP EPS below $3.17. This indicates weaker performance.
Why it matters: Free cash flow over $3.3 billion shows good cash management and strong operations. This helps the company's growth plans.
Confirms:Adjusted free cash flow for Q3 FY26 exceeds $3.3 billion.
Disproves:Adjusted free cash flow for Q3 FY26 is below $3.3 billion.
Why it matters: Insights from the Investor Day can clarify growth strategies and long-term outlook.
Confirms one read:They gave positive updates on growth plans and long-term outlook at Investor Day.
Confirms the other:Negative feedback or lack of clarity on growth strategies at the Investor Day.
Why it matters: A confirmed drop in Medical segment profit may show ongoing problems in that area.
Confirms:Medical segment profit declines by more than 50% year over year.
Disproves:Medical segment profit declines less than 50% year over year.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.